These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Reported results||2007-000394-36||A PHASE III RANDOMISED, MULTICENTRE, DOUBLE-BLIND, THERAPEUTIC EQUIVALENCE STUDY OF BIOSIMILAR G-CSF (PLIVA/MAYNE FILGRASTIM) VERSUS NEUPOGEN (FILGRASTIM – AMGEN) IN SUBJECTS RECEIVING DOXORUBICIN AND...||2008-09-30||due-trials|
|Reported results||2014-005192-89||Post-Marketing Observational Cohort Study of Patients with Inflammatory Bowel Disease (IBD) Treated with CT-P13 in Usual Clinical Practice (CONNECT-IBD)||2018-10-31||due-trials|
|Exempt, with results||2015-002057-35||A Phase 1-2 ascending dose study to assess the pharmacodynamics, pharmacokinetics, and safety of HSP 130 in subjects with non metastatic breast cancer following single dose and multiple dose administr...||2017-10-05||not-yet-due|
|Trial is outside EEC, and reported results||2017-000320-10||A Phase III, Randomized, Double-Blind, Dose-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Dexmedetomidine in Intubated and Mechanically Ventilated Pediatric Intensive Care Unit S...||bad-data|
|Trial is outside EEC, and reported results||2017-000406-38||A Phase II/III, Open-Label, Multicenter, Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Neonates Ages ≥ 28 Weeks to ≤ 44 Weeks Gestational Age||bad-data|
|Trial is outside EEC, and reported results||2017-000407-24||A Phase II, Randomized, Open-Label, Single Center, Pharmacokinetic and Pharmacodynamic Study of Dexmedetomidine in Pediatric Subjects Aged 12 months through <24 months||bad-data|
|Trial is outside EEC, and reported results||2017-000408-71||A Phase II/Ill, Open-Label, Multicenter, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages 28 Weeks to < 36 Weeks Gestational Age||bad-data|